IRVINE, Calif., Sept. 16, 2005 (PRIMEZONE) -- "The recent wave of technology introductions and approvals by biotechnology and pharmaceutical companies affirms our position that firms in these sectors are racing to capture market share with critical products to meet growing market demand," stated SmallCap Sentinel analyst D.R. Clark.
"MIV Therapeutics, Inc. (OTCBB:MIVT) recently announced a milestone scientific achievement related to the development of a new drug delivery system with 'smart' drug-eluting coating technologies," said Clark. It will also showcase the results of a long-term animal study of its proprietary ultra-thin Hydroxyapatite coating at this year's 17th annual Transcatheter Cardiovascular Therapeutics (TCT) 2005 conference in Washington, D.C., according to Clark.
"Such breakthrough news has become an almost daily occurrence in this sector," said Clark. Boston Scientific Corp. (NYSE:BSX) recently gained federal regulatory clearance to market a new device to treat coronary artery blockages. The introduction in Europe of its Endeavor drug-eluting stent by Medtronic Inc. (NYSE:MDT), is partly credited with boosting its share price -- up 15 percent this year after lagging behind its rivals for quite some time. Abbott Labs (NYSE:ABT) recently announced FDA approval for a new device to treat carotid artery disease, making Abbott the second major entry in the U.S. carotid stent market.
"Clearly, the race is on and Biotech and Pharma movers and shakers are jockeying for position in this important market place," said Clark.
The informational report "Innovations in Biotechnology" has been made available free of charge at www.SmallCapSentinel.com and will address stents and stent-related companies including those mentioned above. The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Individuals may also register for future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is a paid advertisement provided for information purposes only and should not be used as the basis for investment decisions. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.